Indeed, when comparing the relative effectiveness of the well-known tTG inhibitor MDC, versus the newly identified TTGM 5826, at inhibiting the growth of cancer cell lines (Table 1), we found that TTGM 5826 was typically about twice as potent as MDC. The gene discussed is TGM2; the disease is cancer.